Mutator phenotype of BCR – ABL transfected Ba/F3 cell lines and its association with enhanced expression of DNA polymerase β

被引:0
|
作者
Y Canitrot
D Lautier
G Laurent
M Fréchet
A Ahmed
AG Turhan
B Salles
C Cazaux
JS Hoffmann
机构
[1] Institut de Pharmacologie et de Biologie Structurale,
[2] CJF INSERM 9503,undefined
[3] Institut Claudius Régaud,undefined
[4] Institut Gustave Roussy,undefined
[5] INSERM U362,undefined
[6] 1 rue C. Desmoulins,undefined
来源
Oncogene | 1999年 / 18卷
关键词
mutator phenotype; DNA polymerase β;
D O I
暂无
中图分类号
学科分类号
摘要
Chronic myelogenous leukemia (CML) is characterized by the Philadelphia chromosome resulting from the translocation t(9-22) producing the chimeric 190 and 210 kDa BCR – ABL fusion proteins. Evolution of the CML to the more agressive acute myelogenous leukemia (AML) is accompanied by increased cellular proliferation and genomic instability at the cytogenetic level. We hypothezised that genomic instability at the nucleotide level and spontaneous error in DNA replication may also contribute to the evolution of CML to AML. Murine Ba/F3 cell line was transfected with the p190 and p210-encoding BCR – ABL oncogenes, and spontaneous mutation frequency at the Na-K-ATPase and the hypoxanthine guanine phosphoribosyl transferase (HPRT) loci were measured. A significant 3 – 5-fold increase in mutation frequency for the transfected cells relative to the untransfected control cells was found. Furthermore, we observed that BCR – ABL transfection induced an overexpression of DNA polymerase β, the most inaccurate of the mammalian DNA polymerases, as well as an increase in its activity, suggesting that inaccuracy of DNA replication may account for the observed mutator phenotype. These data suggest that the Philadelphia abnormality confers a mutator phenotype and may have implications for the potential role of DNA polymerase β in this process.
引用
收藏
页码:2676 / 2680
页数:4
相关论文
共 30 条
  • [1] Mutator phenotype of BCR-ABL transfected Ba/F3 cell lines and its association with enhanced expression of DNA polymerase β
    Canitrot, Y
    Lautier, D
    Laurent, G
    Fréchet, M
    Ahmed, A
    Turhan, AG
    Salles, B
    Cazaux, C
    Hoffmann, JS
    ONCOGENE, 1999, 18 (17) : 2676 - 2680
  • [2] Imatinib mesylate (STI571) prevents the mutator phenotype of Bcr-Abl in hematopoietic cell lines
    van der Kuip, H
    Moehring, A
    Wohlbold, L
    Miething, C
    Duyster, J
    Aulitzky, WE
    LEUKEMIA RESEARCH, 2004, 28 (04) : 405 - 408
  • [3] STI571 reverses the mutator phenotype induced by Bcr-Abl in murine cell lines.
    van der Kuip, H
    Miething, C
    Duyster, J
    Aulitzky, WE
    BLOOD, 2001, 98 (11) : 571A - 571A
  • [4] Distinct mechanisms for growth factor-independence and inhibition of apoptosis by BCR-ABL in Ba/F3 cell line
    Ahmed, A
    Bernard, M
    Bennardo, T
    Kersual, J
    Varet, B
    Turban, AG
    BLOOD, 1995, 86 (10) : 648 - 648
  • [5] Distinct mechanisms for growth factor-independence and inhibition of apoptosis by BCR-ABL in Ba/F3 cell line
    Ahmed, A
    Bernard, M
    Bennardo, T
    Kersual, J
    Varet, B
    Turhan, AG
    BRITISH JOURNAL OF HAEMATOLOGY, 1996, 93 : 283 - 283
  • [6] The BCR/ABL onocogene induces VEGF gene expression in BA/F3 cells through activation of phosphoinositol-3 kinase.
    Mayerhofer, M
    Valent, P
    Griffin, JD
    Sillaber, C
    BLOOD, 2001, 98 (11) : 262B - 263B
  • [7] Constitutive activation of STAT family members in Ba/F3 cells transformed by p210BCR/ABL
    Ilaria, RL
    VanEtten, RA
    BLOOD, 1995, 86 (10) : 1041 - 1041
  • [8] CCR7 is involved in BCR-ABL/STAP-2-mediated cell growth in hematopoietic Ba/F3 cells
    Kubo, Kaori
    Iwakami, Masashi
    Muromoto, Ryuta
    Inagaki, Takuya
    Kitai, Yuichi
    Kon, Shigeyuki
    Sekine, Yuichi
    Oritani, Kenji
    Matsuda, Tadashi
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2015, 463 (04) : 825 - 831
  • [9] Deletion of the Bcr-Abl SH2-domain restores migratory response to SDF-1 in Bcr-Abl expressing Ba/F3 cells.
    Götze, KS
    Keller, U
    Miething, C
    Urlbauer, K
    Marz, S
    Peschel, C
    Duyster, J
    BLOOD, 2003, 102 (11) : 657A - 657A
  • [10] Upon IL-3 withdrawal ABL-kinase deficient BCR-ABL mutants become fully phosphorylated in Ba/F3 cells.
    Beissert, T
    Hansen, M
    Puccetti, E
    Hoelzer, D
    Ottmann, OG
    Ruthardt, M
    BLOOD, 2000, 96 (11) : 94A - 94A